Bernstein Sees No Surprises: Argenx Stock Plummets After Study Setback
Reading Time: 3 minutes
Study Termination: Argenx halts Phase III trial of Efgartigimod SC for Sjögren's syndrome due to missed primary endpoints. Market Reaction: Stock plummets double digits – long-term growth story remains intact. Pipeline Success: Positive Phase II data for celiac disease highlights the potential of the recent M&A strategy. The biotech heavyweight Argenx delivered a cautious trading day for investors: The termination of a far-advanced Phase III study for Sjögren's syndrome resulted in a significant drop in the stock...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
